To proof this hypothesis, we evaluated the influence of the orally available mTOR inhibitor RAD001 (everolimus), applied alone or combined with the dual EGF and VEGF receptor tyrosine kinase inhibitor AEE788 [12], on RCC cell adhesion and proliferation in vitro. The gene discussed is MTOR; the disease is renal cell carcinoma.